Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
- Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Pennsylvania: - Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- WellSpan Medical Oncology and Hematology — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Ephrata Cancer Center — Ephrata, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Pennsylvania: - Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
- Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
- Northeast Radiation Oncology Center — Dunmore, Pennsylvania
- Saint Luke's Hospital-Anderson Campus — Easton, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Pennsylvania: - Research Site — Gettysburg, Pennsylvania
- Research Site — Hershey, Pennsylvania
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Sayre, Pennsylvania
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in Pennsylvania: - Penn Medicine - Lancaster General Hospital — Lancaster, Pennsylvania
- Penn Medicine - Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- Penn Medicine - Pennsylvania Hospital — Philadelphia, Pennsylvania
- Penn Medicine - Chester County Hospital — West Chester, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Pennsylvania: - Alliance Cancer Specialists — Bensalem, Pennsylvania
- Ann B. Barshinger Cancer Institute — Lancaster, Pennsylvania
- Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit — Philadelphia, Pennsylvania
- WellSpan Oncology Research — York, Pennsylvania
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Pennsylvania: - Research Site — Hershey, Pennsylvania
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Pennsylvania: - UPMC Hillman Cancer Center - Magee-Women?s Hospital — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Pennsylvania: - Redeemer Health - Holy Redeemer Hospital — Meadowbrook, Pennsylvania
- Sidney Kimmel Comprehensive Cancer Center - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Pennsylvania: - Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Pennsylvania: - Lehigh Valley Health Network — Allentown, Pennsylvania
- Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania
- Local Institution - 0360 — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …
Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Pennsylvania: - Rittenhouse Hematology/Oncology — Philadelphia, Pennsylvania
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- UPMC Altoona — Altoona, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Pennsylvania: - University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center Cancer UPMC- Magee Women's Hospital — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Pennsylvania: - USOR Alliance Cancer Specialist — Doylestown, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Pennsylvania: - Alliance Cancer Specialists — Horsham, Pennsylvania
- University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- University of Pittsburgh (UPMC) — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Pennsylvania: - Rittenhouse Hematology Oncology — Philadelphia, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- AHN West Penn Hospital — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Pennsylvania: - Penn State Cancer Institute — Hershey, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Pennsylvania: - Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Pennsylvania: - Local Institution - 0014 — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well…
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT05748834
Sites in Pennsylvania: - Alliance Cancer Specialists — Bensalem, Pennsylvania
Phase 2 Recruiting Academic/Other
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants wil…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05534438
Sites in Pennsylvania: - Lehigh Valley Health Network (Data Collection Only) — Allentown, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
Sponsor: Artios Pharma Ltd
NCT ID: NCT05898399
Sites in Pennsylvania: - Jefferson University Hospitals - Kimmel Cancer Center — Philadelphia, Pennsylvania